Media

SynOx Therapeutics announces positive topline results from the Phase 3 TANGENT study

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Number of shares and votes in Oncopeptides

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Vicore publishes the Annual Report for 2025

Intervacc announces breakthrough protection against Streptococcus suis infection in piglets

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Outcome in Oncopeptides’ rights issue